Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologically-based pharmacokinetic modeling

Risk Analysis

Volumn 16, Issue 4, 1996, Pages 571-579

  Vinegar, Allen ^a   Jepson, Gary W ^b  

^a ALION SCIENCE AND TECHNOLOGY   (United States)

^b WRIGHT PATTERSON AIR FORCE BASE   (United States)

Author keywords

Cardiac sensitization threshold; egress time; halon replacement chemical; humans; physiologically based pharmacokinetic modelling

Indexed keywords

BLOOD; CARDIOVASCULAR SYSTEM; CHEMICALS; DRUG DOSAGE; DRUG THERAPY; FLUOROCARBONS; HEALTH RISKS; MATHEMATICAL MODELS; PHARMACOKINETICS;

CARDIAC SENSITIZATION THRESHOLD; CHEMICAL INHALATION EXPOSURES; EGRESS TIME; HALON REPLACEMENT CHEMICALS; HALONS; LOWEST OBSERVABLE ADVERSE EFFECT LEVEL; NO OBSERVABLE ADVERSE EFFECT LEVEL;

RISK ASSESSMENT;

DICHLORODIFLUOROMETHANE;

ARTICLE; DECISION MAKING; DOSE RESPONSE; INHALATION; RISK ASSESSMENT; SENSITIZATION;

EID: 0030220394     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1539-6924.1996.tb01102.x     Document Type: Article

References (22)

1. U.S. Environmental Protection Agency, "SNAP Technical Background Document: Risk Screen on the Use of Substitutes for Class I Ozone-depleting Substances, Fire Suppression and Explosion Protection (Halon Substitutes)," U.S Environmental Protection Agency, Office of Air and Radiation, Stratospheric Protection Division, Washington, D.C. (1994).
2. A. M. Jarabek, J. W. Fisher, R. Rubenstein, J. C. Lipscomb, R. J. Williams, A. Vinegar, and J. N. McDougal, "Mechanistic Insights Aid the Search for CFC Substitutes: Risk Assessment of HCFC-123 as an Example," Risk Anal. 14, 231-250 (1994).
3. M. E. Andersen, "A Physiologically Based Toxicokinetic Description of the Metabolism of Inhaled Gases and Vapors at Steady State," Toxicol. Appl. Pharmacol. 60, 509-526 (1981).
4. R. B. Conolly and M. E. Andersen, "Biologically Based Pharmacodynamic Models: Tools for Toxicological Research and Risk Assessment," Annu. Rev. Pharmacol. Toxicol. 31, 503-523 (1991).
5. H. W. Leung, "Development and Utilization of Physiologically Based Pharmacokmetic Models for Toxicoiogical Applications," J. Toxicol. Environ. Health 32, 247-267 (1991).
6. J. C. Ramsey and M E Andersen, "A Physiologically Based Description of the Inhalation Pharmacokinetics of Styrene in Rats and Humans," Toxicol. Appl. Pharmacol. 73, 159-175 (1984).
7. H. J. Clewell, III and M. E. Andersen, "Risk Assessment Extrapolations and Physiological Modeling," Toxicol. Indust. Health 1(4), 111-131 (1985).
8. R. J. Williams, A. Vinegar, J. N. McDougal, A. M. Jarabek, and J. W. Fisher, "Rat to Human Extrapolation of HCFC-123 Kinetics Deduced from Halothane Kinetics: A Corollary Approach to Physiologically Based Pharmacokinenc Modeling," Fundam Appl. Toxicol. (in press).
9. D. A. Dankovic and A J. Bailer, "The Impact of Exercise and Intersubject Variability on Dose Estimates for Dichloromethane Derived from a Physiologically Based Pharmacokinetic Model," Fundam. Appl. Toxicol. 22, 20-25 (1993).
10. 3I)," Armstrong Laboratory Technical Report AL/OE-TR-1994-0068 (1994)
11. J. R. Creech, R. K. Black, S. K Neurath, M. C. Caracci, R. J. Williams, G. W. Jepson, and A. Vinegar, "Inhalation Uptake and Metabolism of Halon 1301 Replacement Candidates, HFC-227ea, HFC-125, and FC-218," Armstrong Laboratory Technical Report AL/OE-TR-1995-0022 (1995)
12. A. Vinegar, R. J. Williams, J. W. Fisher, and J. N. McDougal, "Dose-Dependent Metabolism of 2,2-Dichloro-1,1,1-trifluoroethane: A Physiologically Based Pharmacokinetic Model in the Male Fischer 344 Rat," Toxicol. Appl. Pharmacol. 129, 103-113 (1994).
13. J. M. Gearhart, D. A. Mahle, R. J. Greene, C. S. Seckel, C. D. Flemming, J. W. Fisher, and H. J. Clewell, III, "Variability of Physiologically Based Pharmacokinetic (PBPK) Model Parameters and Their Effects on PBPK Model Predictions in a Risk Assessment for Perchloroethylene (PCE)," Toxicol. Lett. 68, 131-144 (1993).
14. L. S. Mullin, C. F. Reinhardt, and R. E. Hemingway, "Cardiac Arrhythmias and Blood Levels Associated with Inhalation of Halon 1301," Am. Indust. Hyg. Assoc. J. 40, 653-658 (1979).
15. C. J. Hardy, P. C. Kieran, and I. J. Shaman, "Assessment of the Cardiac Sensitisation Potential (CSP) of a Range of Halogenated Materials," Toxicologist 14, 378 (1994).
16. 50) of Trifluorodichloroethane," Haskell Laboratory Report No. 132-73 (1973).
17. T. J. Kenny, C. K. Shepherd, and C. J. Hardy, "Iodotrifluoromethane and Iodoheptafluoropropane Assessment of Cardiac Sensitisation Potential in Dogs," Armstrong Laboratory Technical Rep. AL/OE-TR-1995-0031 (1995).
18. C. P. Chengelis, "Acute Cardiac Sensitization Study in Dogs with FM-200™ by Inhalation," Wil Research Laboratories, Inc. Ashland, Ohio (1993).
19. M. K. Cahalan, B. H. Johnson, and E. I. Eger, II, "Relationship of Concentrations of Halothane and Enflurane to Their Metabolism and Elimination in Man," Anesthesiology 54, 3-8 (1981).
20. R. L. Carpenter, E I. Eger, II, B H. Johnson, J. D Unadkat, and L. B. Sheiner, "Pharmacokinetics of Inhaled Anesthetics in Humans: Measurements During and After the Simultaneous Administration of Enflurane, Halothane, Isoflurane, Methoxyflurane, and Nitrous Oxide," Anesth. Analg. 65, 575-582 (1986).
21. G. Torri, G Darnia, M. L. Fabiani, and G. Frova, "Uptake and Elimination of Enflurane in Man. A Comparative Study Between Enflurane and Halothane," Brit. J. Anaesth. 44, 789-794 (1972).
22. N. Yasuda, S. H. Lockhart, E. I. Eger, II, R. B. Weiskopf, B. J. Johnson, B. A. Freire, and A. Fassoulaki, "Kinetics of Desflurane, Isoflurane, and Halothane in Humans," Anesthesiology 74, 489-498 (1991).